Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations

AUTOR(ES)

Spain, Brian H.

FONTE

The National Academy of Sciences

RESUMO

BRCA2 mutations predispose carriers mainly to breast cancer. The vast majority of BRCA2 mutations are predicted to result in a truncated protein product. The smallest known cancer-associated deletion removes from the C terminus only 224 of the 3,418 residues constituting BRCA2, suggesting that these terminal amino acids are crucial for BRCA2 function. A series of green fluorescent protein (GFP)-tagged BRCA2 deletion mutants revealed that nuclear localization depends on two nuclear localization signals that reside within the final 156 residues of BRCA2. Consistent with this observation, an endogenous truncated BRCA2 mutant (6174delT) was found to be cytoplasmic. Together, these studies provide a simple explanation for why the vast majority of BRCA2 mutants are nonfunctional: they do not translocate into the nucleus.

Documentos Relacionados

• Role of BRCA1 and BRCA2 mutations in pancreatic cancer
• Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan
• BRCA1 and BRCA2 mutations in a population-based study of male breast cancer
• Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer
• BRCA1 and BRCA2 mutations in central and southern Italian patients